{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:23:45Z","timestamp":1790148225945,"version":"4.0.1"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,4,25]],"date-time":"2005-04-25T00:00:00Z","timestamp":1114387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Overproduction of interleukin\u20101 within the brain is associated with Alzheimer's disease and other neurological conditions. We report that peripheral administration of the acetylcholinesterase inhibitors tacrine, rivastigmine, neostigmine, or EN101 (an antisense oligonucleotide directed at acetylcholinesterase messenger RNA) to mice significantly attenuated the production of interleukin\u20101\u03b2 in the hippocampus and blood, concomitantly with the reduction in acetylcholinesterase activity. These findings demonstrate that cholinergic enhancement produces central and peripheral antiinflammatory effects and suggest a novel therapeutic mechanism for acetylcholinesterase inhibitors. Ann Neurol 2005<\/jats:p>","DOI":"10.1002\/ana.20454","type":"journal-article","created":{"date-parts":[[2005,4,25]],"date-time":"2005-04-25T16:48:49Z","timestamp":1114447729000},"page":"741-745","source":"Crossref","is-referenced-by-count":84,"title":["Acetylcholinesterase inhibitors reduce brain and blood interleukin\u20101\u03b2 production"],"prefix":"10.1002","volume":"57","author":[{"given":"Yehuda","family":"Pollak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Gilboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofra","family":"Ben\u2010Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Ben\u2010Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermona","family":"Soreq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raz","family":"Yirmiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic bases for interleukin\u20101 in disease","volume":"87","author":"Dinarello CA","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.2.233"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(97)00023-3"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/317519"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01321"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2004.02347.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/35067589"},{"key":"e_1_2_5_9_2","first-page":"820","article-title":"Cholinergic therapies for Alzheimer's disease: progress and prospects","volume":"4","author":"Palmer AM","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2003.08.002"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0135647100"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001103"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)01661-1"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb09569.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-06-02239.1998"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.4.563"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri803"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.3.876"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-01-00149.2000"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.11.003"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000125683.74595.2f"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.20454","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.20454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T01:43:25Z","timestamp":1695951805000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.20454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,25]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1002\/ana.20454"],"URL":"https:\/\/doi.org\/10.1002\/ana.20454","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,25]]}}}